Immune response treated with bone marrow mesenchymal stromal cells after stroke

Stroke is a leading cause of death and long-term disability worldwide. Tissue plasminogen activator (tPA) is an effective treatment for ischemic stroke. However, only a small part of patients could benefit from it. Therefore, finding a new treatment is necessary. Bone marrow mesenchymal stromal cell...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in neurology 2022-09, Vol.13, p.991379-991379
Main Authors: Wang, Zili, Wang, Xudong, Liao, Yidong, Chen, Guangtang, Xu, Kaya
Format: Article
Language:English
Subjects:
bone marrow mesenchymal stromal cell
inflammation
Neurology
neuroprotection
stem cell therapy
stroke
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Stroke is a leading cause of death and long-term disability worldwide. Tissue plasminogen activator (tPA) is an effective treatment for ischemic stroke. However, only a small part of patients could benefit from it. Therefore, finding a new treatment is necessary. Bone marrow mesenchymal stromal cells (BMSCs) provide a novel strategy for stroke patients. Now, many patients take stem cells to treat stroke. However, the researches of the precise inflammatory mechanism of cell replacement treatment are still rare. In this review, we summarize the immune response of BMSCs treated to stroke and may provide a new perspective for stem cell therapy.
ISSN:1664-2295
1664-2295
DOI:10.3389/fneur.2022.991379